

# Alan Bonder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/871260/publications.pdf>

Version: 2024-02-01

55  
papers

1,061  
citations

394421

19  
h-index

454955

30  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1316  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-analysis. American Journal of Medicine, 2015, 128, 1314-1321.	1.5	113
2	Utilization of FibroScan in Clinical Practice. Current Gastroenterology Reports, 2014, 16, 372.	2.5	101
3	A randomized placebo-controlled trial of elafibanor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	3.7	77
4	Prevalence of Abnormal Liver Function Tests in Celiac Disease and the Effect of a Gluten-Free Diet in the US Population. American Journal of Gastroenterology, 2015, 110, 1216-1222.	0.4	55
5	Prevalence of Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome. Clinical Gastroenterology and Hepatology, 2011, 9, 609-612.	4.4	52
6	Evaluation of Liver Lesions. Clinics in Liver Disease, 2012, 16, 271-283.	2.1	48
7	Hemostasis, bleeding and thrombosis in liver disease. Journal of Translational Science, 2017, 3, .	0.2	42
8	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	2.8	37
9	Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 1101-1108.	0.4	34
10	Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis. Journal of Hepatology, 2021, 74, 48-57.	3.7	33
11	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
12	Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 1449.	2.4	31
13	Osteoporosis in primary biliary cholangitis. World Journal of Gastroenterology, 2018, 24, 3513-3520.	3.3	29
14	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. American Journal of Medicine, 2017, 130, 744.e1-744.e7.	1.5	28
15	Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2019, 64, 2338-2350.	2.3	28
16	Methotrexate in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to Treatment With Ursodeoxycholic Acid. Digestive Diseases and Sciences, 2010, 55, 3207-3217.	2.3	27
17	Bone Health in Patients With Liver Diseases. Journal of Clinical Densitometry, 2020, 23, 212-222.	1.2	27
18	Contemporary Assessment of Hepatic Fibrosis. Clinics in Liver Disease, 2015, 19, 123-134.	2.1	25

#	ARTICLE	IF	CITATIONS
19	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
20	Long-term outcomes after liver transplantation in the Hispanic population. <i>Liver International</i> , 2020, 40, 437-446.	3.9	20
21	Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. <i>Frontline Gastroenterology</i> , 2019, 10, 401-408.	1.8	14
22	Lipoprotein metabolism in liver diseases. <i>Current Opinion in Lipidology</i> , 2019, 30, 30-36.	2.7	13
23	Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. <i>American Journal of Medicine</i> , 2016, 129, 461-467.	1.5	12
24	A Multicenter Evaluation of Adherence to 4 Major Elements of the Baveno Guidelines and Outcomes for Patients With Acute Variceal Hemorrhage. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 172-177.	2.2	12
25	&lt;p&gt;Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges&lt;/p&gt;. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 17-24.	2.3	12
26	Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 309-310.	4.4	11
27	The Changing Role of Sodium Management in Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 274-284.	0.8	11
28	Suboptimal Implementation of Evidence-based Therapy for Acute Variceal Hemorrhage: A Systematic Review of Observational Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1373-1381.e7.	4.4	10
29	Waitlist mortality and transplant free survival in Hispanic patients listed for liver transplant using the UNOS database. <i>Annals of Hepatology</i> , 2021, 23, 100304.	1.5	9
30	Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation. <i>World Journal of Hepatology</i> , 2015, 7, 28.	2.0	9
31	Primary biliary cholangitis: new treatments for an old disease. <i>Frontline Gastroenterology</i> , 2017, 8, 29-36.	1.8	8
32	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Densitometry</i> , 2020, 23, 223-236.	1.2	8
33	Increased Posttransplant Mortality for Autoimmune Hepatitis Compared With Other Autoimmune Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 648-654.	2.2	8
34	Pharmacologic management of primary sclerosing cholangitis: what's in the pipeline?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 723-729.	3.0	7
35	The influence of equitable access policies and socioeconomic factors on post-liver transplant survival. <i>EClinicalMedicine</i> , 2021, 41, 101137.	7.1	7
36	Management of Autoimmune Liver Diseases after Liver Transplantation. <i>Transplantology</i> , 2021, 2, 162-182.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis. <i>Annals of Hepatology</i> , 2022, 27, 100582.	1.5	6
38	Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law. <i>Liver Cancer</i> , 2014, 3, 428-438.	7.7	5
39	Hospital-level balloon tamponade use is associated with increased mortality for all patients presenting with acute variceal haemorrhage. <i>Liver International</i> , 2018, 38, 477-483.	3.9	5
40	Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 319.	2.4	5
41	Waitlist Mortality and Posttransplant Outcomes in African Americans with Autoimmune Liver Diseases. <i>Journal of Transplantation</i> , 2021, 2021, 1-8.	0.5	5
42	Effective use of FibroTest to generate decision trees in hepatitis C. <i>World Journal of Gastroenterology</i> , 2009, 15, 2617.	3.3	3
43	Waitlist and posttransplantation outcomes of lean individuals with nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2023, 29, 145-156.	2.4	3
44	Current Therapies for Hepatorenal Syndrome. <i>Current Hepatitis Reports</i> , 2014, 13, 74-80.	0.3	2
45	Pregnancy in Chronic Liver Disease: Before and After Transplantation. <i>Annals of Hepatology</i> , 2021, 26, 100557.	1.5	2
46	Cholestatic Liver Disease and Pregnancy: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1068.	2.4	2
47	Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. <i>Pharmaceuticals</i> , 2014, 7, 18-28.	3.8	1
48	Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. <i>Current Hepatology Reports</i> , 2016, 15, 220-229.	0.9	1
49	New OPTN Simultaneous Liver-Kidney Transplant (SLKT) Policy Improves Racial and Ethnic Disparities. <i>Journal of Clinical Medicine</i> , 2020, 9, 3901.	2.4	1
50	Nutrition in Cholestatic Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 1-6.	0.9	1
51	Race/Ethnicity Is Not Independently Associated with Risk of Adverse Waitlist Removal among Patients with HCC Exception Points. <i>Journal of Clinical Medicine</i> , 2021, 10, 5826.	2.4	1
52	Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease – Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan. <i>Digestive Diseases and Sciences</i> , 2013, 58, 889-890.	2.3	0
53	The Reply. <i>American Journal of Medicine</i> , 2016, 129, e263.	1.5	0
54	Thinking Outside of Urso. <i>Clinical Liver Disease</i> , 2020, 16, 38-42.	2.1	0

#	ARTICLE	IF	CITATIONS
55	Current and Emerging Treatment Options for Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2020, 16, 363-365.	0.1	0